SCHEMBL6484606

SCHEMBL6484606

CCN(CC)c1ccc(CCCc2ccc(Nc3ccc(C(=O)O)cc3)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 6/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPT P10636 3/20 0.50
NOX1 Q9Y5S8 2/20 0.50
POLB P06746 2/20 0.50
ESRRB O95718 1/20 0.50
ESRRG P62508 1/20 0.50
GAA P10253 1/20 0.50
MCL1 Q07820 1/20 0.50
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
CNR1 P21554 1/20 0.48
AOC3 Q16853 1/20 0.48
ALDH1A1 P00352 1/20 0.48
RARA P10276 1/20 0.48
MTOR P42345 1/20 0.48
KDM4E B2RXH2 1/20 0.45
GALR3 O60755 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482910 0.87 MEN1 (0.54) MEN1KMT2AMAPTNOX1POLB
SCHEMBL6475709 0.83 MAPT (0.43) RARBMEN1KMT2AMAPTNOX1
SCHEMBL4646270 0.82 RARB (0.73) RARBMEN1KMT2AMAPTPOLB
SCHEMBL6474913 0.81 MEN1 (0.55) MEN1KMT2AMAPTNOX1NPC1
SCHEMBL64440 0.80 MEN1 (0.56) RARBMEN1KMT2AMAPTNOX1
Hydrochloric Acid SCHEMBL2121314 0.78 MAPT (0.54) RARBMEN1KMT2AMAPTNOX1
SCHEMBL11074121 0.78 CNR2 (0.51) RARBMEN1KMT2AMAPTPOLB
SCHEMBL6313104 0.76 ALDH1A1 (0.54) MEN1KMT2AMAPTESRRBESRRG
SCHEMBL6474259 0.75 MEN1 (0.60) MEN1KMT2AMAPTNOX1POLB
SCHEMBL28169496 0.74 MAPT (0.49) MEN1KMT2AMAPTNOX1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 RARB 4655/4885MEN1 474/4885KMT2A 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.